niftify.in

CNBC TV18

Shilpa Medicare submits new drug application to USFDA for kidney disease treatment, stock hits all-time high

Shilpa Medicare Share Price | Shilpa Medicare submitted the NDA to the USFDA by Unicycive Therapeutics, its first regulatory submission from CDMO partnered projects.

The Economic Times

Rocket Returns: This Madhusudhan Kela and Sunil Singhania-owned smallcap stock has rallied 45% since April QIP

Shilpa Medicare, held by Madhusudhan Kela and Sunil Singhania, has returned 45% since its QIP allotment four months ago. Singhania's Abakkus Diversified Alpha Fund-2 received 6 lakh shares, while Kela’s Cohesion MK Best Ideas Sub-Trust was allotted 8.79 lakh shares.

The Economic Times

Shilpa Medicare completes phase-3 trial of novel therapy against nonalcoholic fatty liver disease, shares gain

Shilpa Medicare's shares surged 6.40% on BSE following the successful phase-3 clinical trials of Nor Ursodeoxycholic Acid tablets for Nonalcoholic Fatty Liver Disease. Conducted on 165 patients across India, the trial revealed significant improvements in liver health and reduced fat accumulation with no serious adverse events.

Business Standard

Shilpa Medicare hits fresh high on successful trial of liver fibrosis drug

Shares of Shilpa Medicare were trading at Rs 733.15, up by nearly Rs 36, or 5.15 per cent on the BSE. In contrast, the 30-stock BSE Sensex was trading at 81,714 levels, up 0.77 per cent.

CNBC TV18

Shilpa Medicare shares near record high after 12% surge on this positive development

A total of 165 Nonalcoholic fatty liver disease (NAFLD) patients across the country participated in the study of this new drug, making the trial a multicentric, placebo-controlled double-blinded study.

Mint

Shilpa Medicare soars over 11% to record high on positive phase 3 trial results for fatty liver drug NorUDCA

Shilpa Medicare shares surged over 11% after announcing successful Phase 3 trials for NorUDCA, a drug for Nonalcoholic Fatty Liver Disease (NAFLD).